Loading
Life sciences · Journal article
Food Reviews International · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity is associated with diabetes, dyslipidemia, cardiovascular and liver diseases, representing a major public health challenge. Phenolic compounds have attracted increasing interest due to their potential to modulate pathways involved in these conditions. However, their application is limited by low stability and bioavailability. This narrative review summarizes current evidence on phenolic compounds and nanoencapsulation. In vitro studies demonstrate molecular mechanisms and inhibition of digestive enzymes, whereas preclinical studies consistently report improvements in glucose and lipid metabolism, inflammation, oxidative stress, and liver alterations. Clinical evidence remains limited. Nanoencapsulation may enhance phenolic stability, bioavailability, and biological activity, but further clinical studies are required.